![]() ![]() SBT6050 exposures increased with dose and exhibited a linear PK profile at 0.6 mg/kg and higher. These DLTs resolved with supportive care.Ĭytokine release syndrome (CRS) > Grade 2 was not observed at any dose level. These were mostly Grade 1 or 2 in nature, and no Grade 4 or higher related adverse events were reported.Īt higher dose levels, dose limiting toxicities (DLTs) were observed and included Grade 3 hypotension, injection site reaction, fever, and hypoxia. The most frequent treatment-related adverse events were consistent with immune activation, and included injection site reactions, fever and chills, hypotension, nausea, vomiting, and fatigue. “The signals of anti-tumor activity are encouraging and its complementary mechanism of action with standard-of-care agents makes SBT6050 attractive for combination regimens.” ![]() “The adverse event profile thus far has been very manageable and importantly, suggests the potential to combine with other standard of care agents,” said Samuel Klempner, MD, Medical Oncologist at the Massachusetts General Hospital. ![]() Patients received between 1 and 17 doses of SBT6050.Īs a monotherapy and in combination with pembrolizumab, SBT6050 was generally well-tolerated, with an adverse event profile that is consistent with immune system activation and considered on-mechanism. SBT6050 dose levels ranged from 0.3 to 1.2 mg/kg in the monotherapy dose escalation arm (Part 1), and 0.15 and 0.3 mg/kg in the pembrolizumab combination arm (Part 3). “We look forward to moving into expansion cohorts and to expanding our clinical development plan to include combination with standard-of-care trastuzumab-containing regimens.”Īs of August 1, 2021, 40 patients with advanced or metastatic HER2-expressing or amplified solid tumors were enrolled into the SBT6050-101 trial. “Over this past year, we have gathered compelling data with clear signals of SBT6050’s pharmacological activity, marked by the activation of both the innate and adaptive immune response in patients,” said Laura Shawver, Ph.D., chief executive officer of Silverback. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today presented interim clinical results from a Phase 1/1b clinical study of SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors, at the 2021 European Society for Medical Oncology Congress. This brings Silverback's total funding to $126M to date.SEATTLE-( BUSINESS WIRE)-Silverback Therapeutics, Inc. The company raised $78.5M in a Series B round on Mar 11, 2020. Venture Partners (“USVP”), OrbiMed Advisors LLC, Bristol-Meyers Squibb, Nextech Invest Ltd., Hunt Investment Group and others. Silverback Therapeutics is backed by U.S. Silverback’s lead candidate, SBT6050, directly and potently activates myeloid cells in HER2-containing tumors leading to eradication of the cancer cells and reprogramming of the tumor microenvironment in preclinical models. Silverback’s ImmunoTAC™ platform enables local modulation of powerful biologic pathways enabling innovative therapeutic approaches to oncology, virology and fibrotic diseases. Silverback Therapeutics is developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness - until now. The company is headquartered in Seattle, Washington. Silverback Therapeutics was founded in 2016 by Peter Thompson. Silverback Therapeutics is charting a new path for treating a range of severe diseases. Silverback Therapeutics is a private biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC™ drug conjugates targeting previously inaccessible disease pathways. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |